ICU Medical (NASDAQ:ICUI) Stock Price Expected to Rise, KeyCorp Analyst Says

ICU Medical (NASDAQ:ICUI) had its price objective lifted by KeyCorp from $198.00 to $209.00 in a research report released on Wednesday morning,Benzinga reports. The brokerage currently has an overweight rating on the medical instruments supplier’s stock.

Several other equities research analysts also recently commented on ICUI. StockNews.com downgraded shares of ICU Medical from a “buy” rating to a “hold” rating in a research report on Tuesday. Jefferies Financial Group assumed coverage on ICU Medical in a research report on Monday, October 14th. They issued a “hold” rating and a $183.00 target price for the company. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research note on Wednesday. Finally, Raymond James boosted their price objective on shares of ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research report on Thursday, September 12th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $173.00.

ICU Medical Stock Performance

Shares of NASDAQ ICUI traded down $4.75 during mid-day trading on Wednesday, hitting $170.06. The company had a trading volume of 4,202 shares, compared to its average volume of 273,665. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.41 and a quick ratio of 1.08. The stock has a market cap of $4.15 billion, a price-to-earnings ratio of -38.25 and a beta of 0.66. ICU Medical has a 12 month low of $82.82 and a 12 month high of $196.26. The firm’s 50 day simple moving average is $176.11 and its two-hundred day simple moving average is $141.98.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Tuesday, November 12th. The medical instruments supplier reported $1.23 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.35. ICU Medical had a positive return on equity of 5.04% and a negative net margin of 4.74%. The company had revenue of $580.07 million for the quarter, compared to analysts’ expectations of $574.77 million. As a group, equities research analysts forecast that ICU Medical will post 3.81 earnings per share for the current year.

Insider Activity at ICU Medical

In other news, CEO Vivek Jain sold 12,000 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at $16,320,691.72. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, VP Daniel Woolson sold 2,502 shares of ICU Medical stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $163.22, for a total transaction of $408,376.44. Following the sale, the vice president now owns 13,107 shares of the company’s stock, valued at approximately $2,139,324.54. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $156.04, for a total value of $1,872,480.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $16,320,691.72. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,502 shares of company stock worth $8,445,976 in the last 90 days. 6.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in shares of ICU Medical by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 2,452,720 shares of the medical instruments supplier’s stock worth $263,226,000 after purchasing an additional 11,991 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of ICU Medical by 21.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 311,542 shares of the medical instruments supplier’s stock valued at $36,996,000 after acquiring an additional 55,588 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of ICU Medical by 10.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 301,107 shares of the medical instruments supplier’s stock worth $54,868,000 after purchasing an additional 27,927 shares in the last quarter. Silvercrest Asset Management Group LLC grew its stake in ICU Medical by 109.4% in the first quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier’s stock valued at $29,882,000 after acquiring an additional 145,485 shares during the period. Finally, WCM Investment Management LLC grew its position in shares of ICU Medical by 1.3% in the 3rd quarter. WCM Investment Management LLC now owns 259,481 shares of the medical instruments supplier’s stock valued at $45,272,000 after purchasing an additional 3,407 shares during the period. Institutional investors and hedge funds own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.